459 related articles for article (PubMed ID: 16870915)
21. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
[TBL] [Abstract][Full Text] [Related]
22. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
[TBL] [Abstract][Full Text] [Related]
23. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
[TBL] [Abstract][Full Text] [Related]
24. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.
Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE
J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000
[TBL] [Abstract][Full Text] [Related]
25. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
[TBL] [Abstract][Full Text] [Related]
26. Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.
Griffin ML; Dodd DR; Potter JS; Rice LS; Dickinson W; Sparenborg S; Weiss RD
Am J Drug Alcohol Abuse; 2014 Mar; 40(2):157-62. PubMed ID: 24219166
[TBL] [Abstract][Full Text] [Related]
27. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
[TBL] [Abstract][Full Text] [Related]
28. HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment.
Edelman EJ; Moore BA; Caffrey S; Sikkema KJ; Jones ES; Schottenfeld RS; Fiellin DA; Fiellin LE
J Addict Med; 2013; 7(6):410-6. PubMed ID: 24189173
[TBL] [Abstract][Full Text] [Related]
29. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.
Sullivan LE; Moore BA; O'Connor PG; Barry DT; Chawarski MC; Schottenfeld RS; Fiellin DA
Am J Addict; 2010; 19(1):53-8. PubMed ID: 20132122
[TBL] [Abstract][Full Text] [Related]
30. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
Ling W; Casadonte P; Bigelow G; Kampman KM; Patkar A; Bailey GL; Rosenthal RN; Beebe KL
JAMA; 2010 Oct; 304(14):1576-83. PubMed ID: 20940383
[TBL] [Abstract][Full Text] [Related]
31. Opioid Addiction Treatment Using Buprenorphine-Naloxone In A Community-Based Internal Medicine Practice.
Van Doren BA; Foulks-Rodriguez KA; Yarborough W
J Okla State Med Assoc; 2015 Jul; 108(7):303-9. PubMed ID: 26390769
[TBL] [Abstract][Full Text] [Related]
32. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
33. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.
Moore BA; Barry DT; Sullivan LE; Oʼconnor PG; Cutter CJ; Schottenfeld RS; Fiellin DA
J Addict Med; 2012 Sep; 6(3):205-11. PubMed ID: 22614936
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
[TBL] [Abstract][Full Text] [Related]
35. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
[TBL] [Abstract][Full Text] [Related]
36. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.
Amass L; Kamien JB; Mikulich SK
Drug Alcohol Depend; 2001 Jan; 61(2):173-81. PubMed ID: 11137282
[TBL] [Abstract][Full Text] [Related]
37. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
[TBL] [Abstract][Full Text] [Related]
38. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
Orman JS; Keating GM
Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
[TBL] [Abstract][Full Text] [Related]
39. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
[TBL] [Abstract][Full Text] [Related]
40. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
Cremer LJ; Board A; Guy GP; Schieber L; Asher A; Parker EM
Drug Alcohol Depend; 2022 Mar; 232():109192. PubMed ID: 35065513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]